The European Medicines Agency has adopted revised transparency rules to rationalize the amount of study data that sponsors have to make public via the Clinical Trials Information System (CTIS), the EU portal for making trial-related submissions under the provisions of the Clinical Trials Regulation (CTR).
The emphasis is on publishing fewer documents, but ones that are more meaningful
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?